Studies indicate that the cannabinoid system is impaired in different psychotic disorders. - GreenMedInfo Summary
Cannabinoids for the Treatment of Schizophrenia: An Overview.
Curr Top Med Chem. 2016 Feb 4. Epub 2016 Feb 4. PMID: 26845552
Δ9-tetrahydrocannabinol and its analogues are found to have particular application in psychiatry because of their antipsychotic properties suggesting a therapeutic use as neuroleptic agents in limiting psychotic diseases. These treatments should not only aim to alleviate specific symptoms but alsoattempt to delay/arrest disease progression. In the present review, we reported recent studies supporting the view that the cannabinoid signalling system is a key modulatory element in the activity of the striatum and temporal cortex that has been traditionally associated with psychosis and schizophrenia. This idea is supported by different anatomical, electrophysiological, pharmacological and biochemical data. Furthermore, these studies indicate that the cannabinoid system is impaired in different psychotic disorders, supporting the idea of developing novel pharmacotherapies with compounds that selectively target specific elements of the cannabinoid system.